574 related articles for article (PubMed ID: 15654350)
21. Outcome of allogeneic peripheral blood stem cell transplantation using matched sibling donors in patients with high-risk hematological diseases.
Sohn SK; Kim DH; Kim JG; Sung WJ; Baek JH; Lee NY; Won DI; Suh JS; Lee KS; Lee KB
Eur J Haematol; 2004 Jun; 72(6):430-6. PubMed ID: 15128422
[TBL] [Abstract][Full Text] [Related]
22. Transfusion requirements after bone marrow transplantation from HLA-identical siblings: effects of donor-recipient ABO incompatibility.
Mehta J; Powles R; Singhal S; Horton C; Hamblin M; Zomas A; Saso R; Treleaven J
Bone Marrow Transplant; 1996 Jul; 18(1):151-6. PubMed ID: 8832008
[TBL] [Abstract][Full Text] [Related]
23. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
24. Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: IPD-based meta-analysis of cohort studies.
Kanda J; Ichinohe T; Matsuo K; Benjamin RJ; Klumpp TR; Rozman P; Blumberg N; Mehta J; Sohn SK; Uchiyama T
Transfusion; 2009 Apr; 49(4):624-35. PubMed ID: 19170998
[TBL] [Abstract][Full Text] [Related]
25. ABO incompatibility is associated with increased non-relapse and GVHD related mortality in patients with malignancies treated with a reduced intensity regimen: a single center experience of 221 patients.
Resnick IB; Tsirigotis PD; Shapira MY; Aker M; Bitan M; Samuel S; Abdul-Hai A; Ackerstein A; Or R; Slavin S
Biol Blood Marrow Transplant; 2008 Apr; 14(4):409-17. PubMed ID: 18342783
[TBL] [Abstract][Full Text] [Related]
26. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program.
Kimura F; Sato K; Kobayashi S; Ikeda T; Sao H; Okamoto S; Miyamura K; Mori S; Akiyama H; Hirokawa M; Ohto H; Ashida H; Motoyoshi K;
Haematologica; 2008 Nov; 93(11):1686-93. PubMed ID: 18835834
[TBL] [Abstract][Full Text] [Related]
27. Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome.
Barge RM; Brouwer RE; Beersma MF; Starrenburg CW; Zwinderman AH; Hale G; Waldmann H; den Ottolander GJ; Falkenburg JH; Willemze R; Fibbe WE
Bone Marrow Transplant; 2001 May; 27(10):1053-8. PubMed ID: 11438820
[TBL] [Abstract][Full Text] [Related]
28. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.
Ozcan M; Ustün C; Akçağlayan E; Akan H; Arslan O; Ilhan O; Beksaç M; Gürman G; Demirer T; Arat M; Celebi H; Konuk N; Uysal A; Koç H
Bone Marrow Transplant; 2001 Mar; 27(5):499-505. PubMed ID: 11313683
[TBL] [Abstract][Full Text] [Related]
29. After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B.
Schetelig J; Breitschaft A; Kröger N; Zabelina T; Ebell W; Bornhäuser M; Haack A; Ehninger G; Salama A; Siegert W;
Transfusion; 2005 May; 45(5):779-87. PubMed ID: 15847669
[TBL] [Abstract][Full Text] [Related]
30. Lack of isohemagglutinin production following minor ABO incompatible unrelated HLA mismatched umbilical cord blood transplantation.
Snell M; Chau C; Hendrix D; Fox R; Downes KA; Creger R; Meyerson H; Telen MJ; Laughlin MJ; Lazarus HM; Yomtovian R
Bone Marrow Transplant; 2006 Jul; 38(2):135-40. PubMed ID: 16751785
[TBL] [Abstract][Full Text] [Related]
31. [ABO incompatibility and non myeloablative allogeneic stem cell transplantation].
Malfuson JV; Hicheri Y; Bonin P; Rodet M; Boccaccio C; Pautas C; Kuentz M; Cordonnier C; Noizat-Pirenne F; Maury S
Transfus Clin Biol; 2007 Aug; 14(3):327-33. PubMed ID: 17462938
[TBL] [Abstract][Full Text] [Related]
32. Major ABO-incompatible hematopoietic stem cell transplantation: study of post-transplant pure red cell aplasia and endothelial cell chimerism.
Mueller RJ; Stussi G; Odermatt B; Halter J; Schanz U; Seebach JD
Xenotransplantation; 2006 Mar; 13(2):126-32. PubMed ID: 16623806
[TBL] [Abstract][Full Text] [Related]
33. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
34. Treatment of pure red cell aplasia after major ABO-incompatible peripheral blood stem cell transplantation by induction of chronic graft-versus-host disease.
Yamaguchi M; Sakai K; Murata R; Ueda M
Bone Marrow Transplant; 2002 Oct; 30(8):539-41. PubMed ID: 12379896
[TBL] [Abstract][Full Text] [Related]
35. Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?
Mehta J; Powles R; Sirohi B; Treleaven J; Kulkarni S; Saso R; Tait D; Singhal S
Bone Marrow Transplant; 2002 May; 29(10):853-9. PubMed ID: 12058235
[TBL] [Abstract][Full Text] [Related]
36. Minor ABO-mismatches are risk factors for acute graft-versus-host disease in hematopoietic stem cell transplant patients.
Ludajic K; Balavarca Y; Bickeböller H; Rosenmayr A; Fischer GF; Faé I; Kalhs P; Pohlreich D; Kouba M; Dobrovolna M; Greinix HT
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1400-6. PubMed ID: 19822299
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic haemopoietic cell transplants in Australia, 1996--a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow.
Nivison-Smith I; Bradstock KF; Szer J; Durrant S; Dodds A; Hermann R; Schwarer AP; Gibson J; To LB; Arthur C;
Bone Marrow Transplant; 2001 Jul; 28(1):21-7. PubMed ID: 11498740
[TBL] [Abstract][Full Text] [Related]
38. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.
Schmitz N; Beksac M; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; Apperley J; Szerm J; Bradstock K; Buzyn A; Schlegelberger B; Matcham J; Gratwohl A
Haematologica; 2005 May; 90(5):643-8. PubMed ID: 15921379
[TBL] [Abstract][Full Text] [Related]
39. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
Moore J; Nivison-Smith I; Goh K; Ma D; Bradstock K; Szer J; Durrant S; Schwarer A; Bardy P; Herrmann R; Dodds A
Biol Blood Marrow Transplant; 2007 May; 13(5):601-7. PubMed ID: 17448920
[TBL] [Abstract][Full Text] [Related]
40. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies.
Meisel R; Laws HJ; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Schmitz M; Fischer J; Göbel U; Enczmann J; Dilloo D
Biol Blood Marrow Transplant; 2007 Nov; 13(11):1338-45. PubMed ID: 17950920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
